Drugs Xagena
The FDA ( Food and Drug Administration ) has granted accelerated approval to Lynparza ( Olaparib ), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes, as ...
The European Medicines Agency ( EMA ) has approved Lynparza ( Olaparib ) tablets ( 300mg twice daily ) for use as a maintenance therapy for patients with Platinum-sensitive relapsed high-grade, epithe ...
The European Commission ( EC ) has approved Lynparza ( Olaparib ) as a 1st-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer. The licensed indication is as a maintenanc ...
Lynparza ( Olaparib ) has been approved in the European Union ( EU ) for patients with metastatic castration-resistant prostate cancer ( mCRPC ) with breast cancer susceptibility gene 1/2 ( BRCA1/2 ) ...
Some 90% of ovarian cancer are of epithelial cell type: among them, 75% of cases are represented by the high-grade serous ovarian cancer (HG-SOC) and the remaining 10% are non-epithelial ovarian cance ...
